News: Clonidine transdermal patches can cause confusion in dosage strength or frequency - - RNweb
Web Poll
Have you seen a rise in cases of community-acquired MRSA at your facility?
Yes
No
Yes
83%
No
17%
Thank you for participating in our poll.
Subscribe to our sister nursing publications

Get a FREE subscription to:


Healthcare Traveler

News: Clonidine transdermal patches can cause confusion in dosage strength or frequency

Source: RN

Clonidine transdermal therapeutic system (CATAPRES-TTS) patches often do not include the name or strength of the drug on the patch itself, which can lead to errors if the dose of a patch is changed, or if the patient requires multiple patches, according to the Institute for Safe Medication Practices (ISMP). Patches can be worn for a week at a time, and numerous caregivers can interact with a patient during that time. Upon visualization, those caregivers cannot determine the drug or dose, or even whether it's a medication patch or some sort of adhesive bandage. A nurse therefore can receive a new order for a patch or oral dose of clonidine and not realize the patient is already wearing a clonidine patch. The manufacturer suggests labeling the patch cover and placing it over the patch. Each patch also includes a code: BI 33 means it's a 0.3 mg patch, BI 32 is 0.2 mg, and BI 31 is 0.1 mg. ISMP suggests you ask the pharmacy to add the code to the drug profile in its computer so it appears on computer-generated medication records for reference.

Anonymous patches (2008). Nurse Advise-ERR, 6(5), 3.

Other Articles from RN
Chocolate lovers rejoice!
Patients may benefit from new fibromyalgia drug
Profile of risk factors for Alzheimer's expanded
New drug approved for renal cell carcinoma
Innovations in Practice: Get moving to fight diabetes
Make This Page Your Home Page!
Customized Patient Education Handouts
Clinical Resources
powered by Mediwire
SEARCH:
 
View All Topics
Source: RN,
Click here